FDA approves first-ever RNAi-based therapy
The FDA approved the first-ever therapy based on a technique known as RNA interference.
by Kate Sheridan
Aug 10, 2018
2 minutes
The Food and Drug Administration on Friday approved a landmark rare disease treatment — the first to rely on a Nobel-prize-winning technique known as RNA interference, which silences disease-causing genes.
The approval is a major accomplishment for Cambridge, Mass.-based Alnylam, which will be marketing the drug, patisiran, as Onpattro and which has been working to bring an
You’re reading a preview, subscribe to read more.
Start your free 30 days